<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Extrapulmonary manifestations of alpha-1 antitrypsin deficiency</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Extrapulmonary manifestations of alpha-1 antitrypsin deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Extrapulmonary manifestations of alpha-1 antitrypsin deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alpha-1 antitrypsin (AAT) is a serine protease inhibitor (PI) that is produced in hepatocytes. AAT deficiency is characterized by autosomal co-dominant inheritance of mutations in the alpha-1 antitrypsin gene (MIM 107400) [<a href="#rid1">1</a>]. AAT deficiency is associated with lung, liver, skin disease, and possibly other organ diseases [<a href="#rid2">2</a>].</p><p>The extrapulmonary manifestations of AAT deficiency will be reviewed here. The pulmonary manifestations and treatment of AAT deficiency are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/1434.html" rel="external">"Treatment of alpha-1 antitrypsin deficiency"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">HEPATIC DISEASE</span><span class="headingEndMark"> — </span>Some AAT-deficient genotypes are associated with increased risk for certain liver disorders, such as neonatal hepatitis, cirrhosis both in children and adults, and hepatocellular carcinoma [<a href="#rid3">3-9</a>]. Approximately 10 to 15 percent of newborns with these genotypes develop some form of hepatic disease, and approximately 10 to 15 percent of affected adults develop hepatic disease [<a href="#rid10">10</a>]. Among never smokers, the prevalence of liver disease at death is higher (28 percent) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3402615971"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The two alleles that are most commonly associated with liver disease, Z and M(malton), are associated with accumulation of AAT protein in the hepatocyte  (<a class="graphic graphic_table graphicRef103267" href="/z/d/graphic/103267.html" rel="external">table 1</a>). Other rare alleles, M(duarte), M(nichinan), S, and S(iiyama), are also known to cause intrahepatocytic accumulation [<a href="#rid10">10,12-14</a>]. Liver disease has not yet been described in these latter disorders, but too few individuals have been identified to reach a conclusion [<a href="#rid13">13,15</a>]. The PI Null (Hong Kong) is a variant in which no serum AAT is detected, but truncated protein can be found in the endoplasmic reticulum in the hepatocyte in vitro. Whether clinical liver disease can accompany this variant is unclear based on sparse clinical experience [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The pathogenesis of the liver injury in AAT deficiency differs from that of the pulmonary disease.</p><p>Pulmonary disease is primarily due to a so-called "toxic loss of function" abnormality, ie, destruction of elastin by elastase and other proteases, the activity of which is increased because of deficiency of the elastase inhibitor AAT. Polymers of Z-type AAT protein have been shown to be chemotactic for neutrophils, which supports the hypothesis that polymers in the lung (either circulating or produced locally by alveolar macrophages) can contribute to emphysema through a so-called "toxic gain of function" abnormality. (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a>.)</p><p>In contrast, liver disease is caused by pathologic polymerization of the variant AAT, resulting in intrahepatocyte accumulation of AAT molecules (also called a "toxic gain of function" abnormality), rather than a proteolytic mechanism [<a href="#rid17">17-19</a>]. Pathologically, the accumulated AAT appears as inclusions within hepatocytes that stain positively with periodic acid-Schiff (PAS) reagent but resist digestion by diastase  (<a class="graphic graphic_picture graphicRef71334" href="/z/d/graphic/71334.html" rel="external">picture 1</a>).</p><p>This mechanism of liver disease is supported by two main observations [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease has only been observed in individuals with alleles causing intrahepatocyte accumulation, eg, Z, M(malton).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease has not been observed among PI*Null-Null individuals. These patients have no circulating AAT, which predicts the greatest proteolytic risk. However, the liver is not affected because there is no accumulation of AAT protein within the hepatocyte.</p><p></p><p>Intrahepatocyte accumulation of Z-type molecules occurs within the rough endoplasmic reticulum and results from abnormal folding and aggregation of variant AAT molecules in a mechanism called loop-sheet polymerization [<a href="#rid7">7,20-22</a>]. Factors promoting loop-sheet polymerization include increased temperature and increased concentration of Z-type protein [<a href="#rid20">20</a>]. Polypeptides that inhibit loop-sheet polymerization of variant Z-type molecules have been explored [<a href="#rid23">23</a>].</p><p>However, abnormal folding does not explain why only some PI*ZZ individuals develop liver disease. It appears that a second defect is also required: decreased degradation of the Z-type molecules within the endoplasmic reticulum, possibly through defects in the proteasomal or autophagic degradation pathways [<a href="#rid24">24</a>], which further promotes the intrahepatocyte accumulation of AAT [<a href="#rid18">18</a>].</p><p>It is unclear how the accumulation of Z-type protein within the rough endoplasmic reticulum causes liver cell injury. Possible mechanisms include simple cell engorgement related to mass build-up, and release of lysosomal enzymes caused by cell engorgement, with resultant cell damage. Some investigators have also suggested that the PI*ZZ genotype predisposes to hepatitis and that the liver damage is mediated by viral infection [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Risk and natural history</span></p><p class="headingAnchor" id="H3878406235"><span class="h3">Childhood onset</span><span class="headingEndMark"> — </span>Available data about the risk and natural history of liver disease in AAT-deficient individuals are based primarily on studies of PI*Z homozygotes identified by screening at birth. One study of 200,000 Swedish newborns, for example, found 127 PI*Z homozygotes (prevalence 1/1575) who were then followed into adolescence and adulthood [<a href="#rid3">3,26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Liver damage occurred in 14 of these neonates (11 percent), most commonly presenting as neonatal hepatitis with cholestasis beginning between four days and four months after birth and persisting for up to 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other clinical presentations among newborns included hepatomegaly with elevated aminotransferase levels (but without hyperbilirubinemia), ascites, and bleeding (often umbilical, superficial, or intracranial [5 percent of affected newborns]). Early presentation of AAT-associated liver disease during the neonatal period is not necessarily associated with a worse prognosis compared with later presentation during childhood [<a href="#rid3">3,27</a>].</p><p></p><p>Follow-up of PI*Z homozygotes identified at birth shows a variable natural history of AAT deficiency-associated liver disease [<a href="#rid28">28</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Three of 14 children (21 percent) with neonatal hepatitis developed cirrhosis by age seven, two of whom died of complications of cirrhosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By age eight, the remaining 11 children were clinically well but frequently had elevated aminotransferase levels. A few children (14 percent) developed newly elevated values of gamma glutamyl transferase without antecedent neonatal hepatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Later follow-up at age 12 showed elevated aminotransferase levels in 20 percent of those with icteric neonatal hepatitis and in 14 percent with anicteric hepatitis. However, none of these adolescents had clinically evident liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By age 18, only 12 percent had elevations in serum alanine aminotransferase or gamma glutamyl transferase [<a href="#rid6">6</a>].</p><p></p><p>Others have summarized the natural history of liver dysfunction in children with the PI*ZZ genotype [<a href="#rid29">29</a>]. Of the 10 to 15 percent of newborns with neonatal hepatitis, 5 percent remained jaundiced and developed progressive cirrhosis with death from complications of cirrhosis within the first year of life. In the remaining children, four clinical patterns of liver evolution were apparent, each occurring in approximately 25 percent of cases:</p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of hepatitis by ages 3 to 10 years without hepatomegaly or splenomegaly</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of cirrhosis between age six months and 17 years, often causing death from complications of end-stage liver disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologic evidence of cirrhosis but with survival through the first decade with few sequelae</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent elevation of liver function tests without cirrhosis</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Adult onset</span><span class="headingEndMark"> — </span>Adults with at-risk alleles (eg, Z and M[malton]) may develop adult-onset chronic hepatitis, cirrhosis, or hepatocellular carcinoma, the former often occurring without antecedent childhood liver disease [<a href="#rid9">9,11,30-33</a>]. Approximately 40 percent of adults with PI*ZZ have histologically significant liver injury and cirrhosis [<a href="#rid32">32</a>]. Male sex, the metabolic syndrome, and obesity have been identified as risk factors for progression to advanced liver disease in adulthood among patients with severe AAT deficiency [<a href="#rid34">34-36</a>]. The exact effect of alcohol consumption is unclear, but alcohol misuse appears to hasten progression of AAT-associated liver fibrosis [<a href="#rid36">36</a>]. In contrast, viral hepatitis does not appear to increase the risk of progressive hepatic failure [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p class="headingAnchor" id="H2650073154"><span class="h2">Management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – The American Thoracic Society (ATS) guidelines suggest routine assessment of liver function tests in patients with known AAT deficiency and pulmonary symptoms [<a href="#rid10">10</a>]. However, in a cross sectional study of 647 adults with AAT deficiency, the prevalence of an elevated alanine aminotransferase level was 8 percent, which did not differ from normal controls [<a href="#rid35">35</a>]. In this study, the sensitivity of an elevated alanine aminotransferase (ALT) level for identifying self-reported liver disease was 12 percent. In a separate study of 49 PI*ZZ individuals, abnormal echogenicity on liver ultrasound demonstrated 100 percent sensitivity and 42 percent positive predictive value for detecting severe fibrosis or cirrhosis [<a href="#rid37">37</a>]. Also, an elevated ALT (&gt;70 U/L) and a platelet count &lt;174,000 demonstrated high sensitivity (70 and 50 percent, respectively), leading to a suggestion that conventional liver function tests, platelet count, and abdominal ultrasound represent an effective screening strategy for severe liver disease among at-risk individuals. </p><p></p><p class="bulletIndent1">Pending greater clarity on the ideal testing protocol, our practice is to assess serum aminotransferases (eg, alanine aminotransferase, aspartate aminotransferase), alkaline phosphatase, and bilirubin annually [<a href="#rid10">10</a>]. Ultrasound-based elastography is increasingly used to monitor for fibrosis, although the optimal frequency of screening has not been determined [<a href="#rid38">38-40</a>]. (See  <a class="medical medical_review" href="/z/d/html/96717.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatocellular carcinoma screening</strong> – Hepatocellular carcinoma can occur in patients with AAT deficiency in the absence of accompanying cirrhosis. In patients with AAT deficiency and established cirrhosis, targeted testing for hepatocellular carcinoma has been recommended with ultrasound examination of the liver every six months [<a href="#rid36">36,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults", section on 'Our approach to surveillance'</a>.)</p><p></p><p class="bulletIndent1">A large longitudinal registry study found a highly increased risk of hepatocellular carcinoma over a median 17-year follow-up in both men (hazard ratio [HR] 47) and women (HR 6) with PI*ZZ, even after controlling for age, smoking status, and baseline liver disease [<a href="#rid9">9,36,41</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Augmentation of AAT is ineffective in liver disease, as the mechanism of liver injury is the accumulation of mutant Z protein in hepatocytes rather than protease deficiency [<a href="#rid32">32</a>]. Management traditionally focuses on supportive measures to prevent or reduce the complications of chronic liver disease. For adults with end-stage liver disease due to AAT, liver transplantation has resulted in a five-year survival of 85 percent [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p></p><p class="bulletIndent1">Fazirsiran, an investigational inhibitory RNA (RNAi) therapeutic that targets AAT and Z-AAT messenger RNA for degradation, has been evaluated in a small phase 2 study of 16 patients with PI*ZZ AAT deficiency [<a href="#rid44">44</a>]. Subcutaneous administration of fazirsiran led to an 83 percent decrease in total liver Z-AAT after 24 to 48 weeks (95% CI 76-90 percent). Improvements were also seen in histologic liver abnormalities, including a reduction in portal inflammation scoring in two-thirds of patients. In 15 patients who had biopsies at baseline and follow-up, histologic fibrosis regression occurred in seven patients and progression was observed in two. Pulmonary function remained stable, and there were no exacerbations among six patients with emphysema on AAT augmentation. Additional data are needed to establish the utility of this agent in clinical practice. </p><p></p><p class="headingAnchor" id="H6"><span class="h1">SKIN DISEASE</span><span class="headingEndMark"> — </span>The major dermatologic manifestation of alpha-1 antitrypsin (AAT) deficiency, although rare, is necrotizing panniculitis. Other possible dermatologic associations with AAT deficiency include systemic vasculitis, psoriasis, urticaria, and angioedema [<a href="#rid10">10</a>]. (See <a class="local">'ANCA-positive vasculitis'</a> below.)</p><p class="headingAnchor" id="H176414"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Necrotizing panniculitis is characterized by inflammatory lesions of the skin and subcutaneous tissue [<a href="#rid45">45-48</a>]. The mean age of onset is 40 years old [<a href="#rid10">10</a>]. Patients present with one or more hot, painful, red nodules or plaques on the thigh or buttocks [<a href="#rid49">49</a>]. These lesions can be difficult to distinguish from panniculitis due to other causes, but may be more inflammatory with an oily yellow discharge and more pronounced histologic evidence of acute inflammation  (<a class="graphic graphic_table graphicRef65180" href="/z/d/graphic/65180.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis", section on 'Enzymatic destruction'</a>.)</p><p>Panniculitis is the least common of the well-recognized complications of AAT deficiency, with relatively few cases reported in the English literature [<a href="#rid45">45,48-52</a>]. The prevalence among AAT-deficient subjects is probably less than one case per thousand. In rare instances, panniculitis may be accompanied by a polyserositis.</p><p class="headingAnchor" id="H7"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Panniculitis has been reported to occur in a variety of genotypes, including PI*ZZ, PI*MZ, PI*SS, and PI*MS [<a href="#rid49">49</a>]. Seventy percent of reported cases have occurred in patients with PI*ZZ genotype and severe AAT deficiency [<a href="#rid49">49</a>]. Similar to the pathophysiology of emphysema in such individuals, the panniculitis is thought to result from a "toxic loss of function" with unopposed proteolysis in the skin. In a case report, skin biopsy revealed Z type AAT polymers in affected areas, raising the possibility that AAT polymers in the skin contribute to the observed inflammation [<a href="#rid53">53</a>]. Further study is needed before this pathogenetic mechanism is established. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H176869"><span class="h2">Diagnosis and therapy</span><span class="headingEndMark"> — </span>As necrotizing panniculitis is a rare manifestation of AAT deficiency, a deep excisional biopsy is usually obtained to establish the diagnosis. Characteristic histologic findings on skin biopsy include lobular fat necrosis of the lower reticular dermis and abundant neutrophil influx interspersed with normal-appearing fat and necrotic panniculus [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis", section on 'Biopsy'</a>.)</p><p>Based upon the presumed pathophysiologic mechanism of unopposed proteolysis, treatment of panniculitis in AAT-deficient subjects has focused on restoring antiprotease activity. Though off-label in this setting, intravenous infusion of purified AAT, sometimes with higher than the approved doses for emphysema management, has ameliorated the panniculitis in some patients [<a href="#rid46">46,48,49,54</a>].</p><p>Other treatments have included <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> (100 mg/day for several weeks) and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg/day for as long as several months) [<a href="#rid46">46,49,51,54,55</a>]. However, evidence in support of these therapies is limited. Doxycycline is believed to act by scavenging reactive oxygen species produced by neutrophils and/or by slowing the breakdown of matrix proteins by elastase. Topical and systemic glucocorticoids have not been helpful [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H8"><span class="h1">OTHER ASSOCIATIONS</span><span class="headingEndMark"> — </span>Associations between alpha-1 antitrypsin (AAT) deficiency and vascular disease, inflammatory bowel disease, glomerulonephritis, and vasculitis have been proposed but not definitively established.</p><p class="headingAnchor" id="H9"><span class="h2">Vascular disease</span><span class="headingEndMark"> — </span>Vascular complications are a rare and less well-established consequence of the PI*ZZ genotype [<a href="#rid56">56,57</a>]. A number of vascular abnormalities have been suggested, including abdominal and intracranial aneurysms, arterial fibromuscular dysplasia, and venous thromboembolism (VTE), all based on the principle that unopposed proteolytic activity damages vessel walls in severely deficient individuals [<a href="#rid10">10,49</a>]. In one cohort study, VTE was increased by approximately 4.5-fold in patients with the PI*ZZ genotype [<a href="#rid58">58</a>]. Rare compound heterozygotes of the Z allele with non-benign missense or loss-of-function variants showed a similar VTE predisposition.</p><p>In addition, one allele (so-called AAT Pittsburgh) is characterized by substitution of an arginine for a methionine at position 358, causing the protein to mimic the hemorrhagic effects of antithrombin III [<a href="#rid59">59</a>]. Two individuals with AAT Pittsburgh have thus far been identified, one of whom died of massive bleeding when the acute phase reactant properties of the AAT protein caused levels of the Pittsburgh variant to rise after a viral infection [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Inflammatory bowel disease</span><span class="headingEndMark"> — </span>Data are conflicting regarding an association between AAT and inflammatory bowel disease. It has been hypothesized that decreased antiprotease activity in the bowel may promote local injury and progression to inflammatory bowel disease [<a href="#rid60">60</a>]. One case-control study from Sweden found that significantly more patients with ulcerative colitis were PI*MZ than in the general population (8.5 versus 4.7 percent) and that PI*MZ individuals tended to have more severe colitis [<a href="#rid61">61</a>]. However, a second study from Germany comparing 135 patients with either Crohn's disease or ulcerative colitis with controls found no such associations [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Glomerulonephritis</span><span class="headingEndMark"> — </span>Glomerular disease is an uncommon finding in AAT. Two different types have been described, one related to AAT and the other to the development of liver failure:</p><p class="bulletIndent1"><span class="glyph">●</span>A proliferative glomerulonephritis, most often of the membranoproliferative type, rarely occurs in association with the PI*ZZ genotype [<a href="#rid63">63-66</a>]. Why this might occur is not clear. Virtually all reported patients have had cirrhosis, suggesting that serious liver disease plays an important role in the development of this immune complex disorder. (See  <a class="medical medical_review" href="/z/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IgA nephropathy is described in association with hepatic cirrhosis due to AAT deficiency [<a href="#rid67">67-69</a>]. Glomerular IgA deposition is a common finding in hepatic cirrhosis of any cause. Impaired removal of IgA-containing complexes (such as those directed against alimentary antigens) by the Kupffer cells in the liver is thought to predispose to IgA deposition in the kidney. One study evaluated 18 children with end-stage liver disease due mostly to AAT deficiency or biliary atresia in whom renal biopsy was performed at the time of hepatic transplantation [<a href="#rid67">67</a>]. Pathologic evidence of either a mesangial proliferative or membranoproliferative glomerulonephritis was seen in all; most patients had IgA nephropathy. (See  <a class="medical medical_review" href="/z/d/html/3112.html" rel="external">"IgA nephropathy: Clinical features and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">ANCA-positive vasculitis</span><span class="headingEndMark"> — </span>A putative association between vasculitis and AAT deficiency is based on reports from many countries that AAT variants, homozygous ZZ and SS, heterozygous Z, and SZ, occur in higher than expected frequency among individuals with multisystem vasculitides  (<a class="graphic graphic_table graphicRef59808" href="/z/d/graphic/59808.html" rel="external">table 3</a>) [<a href="#rid70">70-74</a>]. In a series of 433 patients with granulomatosis and polyangiitis, the odds ratio for the PI*ZZ, PI*SZ, or PI*SS genotypes was markedly elevated (OR 14.58, 95% CI 2.33-infinity), compared with the normal MM genotype [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p>The association between AAT deficiency and cytoplasmic-antineutrophil cytoplasmic antibody (C-ANCA) positive vasculitis is strengthened by plausible pathogenetic mechanisms. For example, in the extravascular fluid, AAT plays an important role as an inhibitor of proteinase-3, a neutrophil elastase-like serine protease located in the primary granules of the neutrophil. Unchecked, proteinase-3 exerts potent tissue-destructive capacity, so a deficiency of AAT could conceivably trigger an auto-immune response by allowing increased extracellular exposure to proteinase-3 [<a href="#rid75">75</a>]. Alternatively, linkage disequilibrium might promote inheritance of important autoimmunity genes along with abnormal AAT genotypes [<a href="#rid76">76</a>]. Finally, though unproven, it is conceivable that circulating Z or S polymers could prompt a vasculitic response. (See  <a class="medical medical_review" href="/z/d/html/3074.html" rel="external">"Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis"</a>.)</p><p>Systemic vasculitis with perinuclear-ANCA and specificity for myeloperoxidase has been described in patients with AAT deficiency [<a href="#rid73">73,77</a>]. Rare cases of ANCA-negative vasculitis (eg, eosinophilic granulomatosis with polyangiitis, Henoch Schönlein vasculitis) have also been reported in AAT deficient patients [<a href="#rid78">78,79</a>].</p><p>These findings have prompted a suggestion from the joint American Thoracic Society (ATS)/European Respiratory Society (ERS) in favor of genetic testing for AAT deficiency in individuals with C-ANCA positive vasculitis [<a href="#rid10">10</a>].</p><p>The ATS and ERS statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS website at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thoracic.org%2Fstatements%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUr3SRsNf6YBT3Fr3MIDgZvpZGvZXjM5qSgaeGcxqQwZtc&amp;TOPIC_ID=1429" target="_blank">www.thoracic.org/statements</a>.</p><p class="headingAnchor" id="H1330865498"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H176990"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Depending on the specific variant of the alpha-1 antitrypsin (AAT) gene (OMIM 107400), a variety of extrapulmonary manifestations may occur in AAT deficient individuals  (<a class="graphic graphic_table graphicRef103267" href="/z/d/graphic/103267.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The types of liver disease associated with AAT deficiency include neonatal hepatitis, hepatomegaly with elevated aminotransferase levels, ascites, cirrhosis, and hepatocellular carcinoma. (See <a class="local">'Hepatic disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The AAT variant that is most commonly associated with liver disease is Z. The pathogenesis of liver disease in AAT deficient individuals relates to accumulation of abnormal AAT protein within hepatocytes. The rare alleles, M(malton), M(duarte), M(nichinan), S, and S(iiyama), are also known to cause intrahepatocytic accumulation, but it is not known whether they cause clinically significant liver disease. (See <a class="local">'Hepatic disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among children with AAT deficiency and neonatal hepatitis, a quarter will have resolution of hepatitis by age 3 to 10 years without hepatomegaly or splenomegaly; a quarter will develop cirrhosis between age six months and 17 years, often causing end-stage liver disease; a quarter will have histologic evidence of cirrhosis but with few sequelae; and a quarter will have persistent elevation of liver function tests without cirrhosis. (See <a class="local">'Risk and natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults with the at-risk alleles (eg, Z, M[malton]) may develop cirrhosis or hepatocellular carcinoma without antecedent childhood liver disease. (See <a class="local">'Adult onset'</a> above and  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Determining the cause of cirrhosis'</a> and  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Necrotizing panniculitis, which presents with one or more hot, painful, red nodules or plaques on the thigh or buttocks, is a rare manifestation of AAT deficiency. It occurs in patients with more severe AAT deficiency and those with the PI*ZZ, PI*MZ, PI*SS, and PI*MS genotypes. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatments for panniculitis include intravenous AAT augmentation therapy, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. (See <a class="local">'Diagnosis and therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/1434.html" rel="external">"Treatment of alpha-1 antitrypsin deficiency", section on 'Intravenous augmentation therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associations between AAT and several other disease processes (eg, vascular disease, inflammatory bowel disease, glomerulonephritis, and systemic vasculitis) have been proposed, but not definitively established. (See <a class="local">'Other associations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">http://omim.org/entry/107400 (Accessed on June 29, 2015).</li><li><a class="nounderline abstract_t">Greulich T, Nell C, Hohmann D, et al. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294:1316.</a></li><li><a class="nounderline abstract_t">Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204:345.</a></li><li><a class="nounderline abstract_t">Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 1986; 314:736.</a></li><li><a class="nounderline abstract_t">Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969; 73:934.</a></li><li><a class="nounderline abstract_t">Mahadeva R, Chang WS, Dafforn TR, et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest 1999; 103:999.</a></li><li><a class="nounderline abstract_t">Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103:2136.</a></li><li><a class="nounderline abstract_t">Hiller AM, Ekström M, Piitulainen E, et al. Cancer risk in severe alpha-1-antitrypsin deficiency. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.</a></li><li><a class="nounderline abstract_t">Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 2008; 63:1091.</a></li><li><a class="nounderline abstract_t">Salahuddin P. Genetic variants of alpha1-antitrypsin. Curr Protein Pept Sci 2010; 11:101.</a></li><li><a class="nounderline abstract_t">Seyama K, Nukiwa T, Takabe K, et al. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 1991; 266:12627.</a></li><li><a class="nounderline abstract_t">Janciauskiene S, Eriksson S, Callea F, et al. Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin. Hepatology 2004; 40:1203.</a></li><li><a class="nounderline abstract_t">Birrer P, McElvaney NG, Chang-Stroman LM, Crystal RG. Alpha 1-antitrypsin deficiency and liver disease. J Inherit Metab Dis 1991; 14:512.</a></li><li><a class="nounderline abstract_t">Frazier GC, Siewertsen MA, Hofker MH, et al. A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure. J Clin Invest 1990; 86:1878.</a></li><li><a class="nounderline abstract_t">Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax 2004; 59:529.</a></li><li><a class="nounderline abstract_t">Teckman JH, Qu D, Perlmutter DH. Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Hepatology 1996; 24:1504.</a></li><li><a class="nounderline abstract_t">Wu Y, Whitman I, Molmenti E, et al. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A 1994; 91:9014.</a></li><li><a class="nounderline abstract_t">Lomas DA, Finch JT, Seyama K, et al. Alpha 1-antitrypsin Siiyama (Ser53--&gt;Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem 1993; 268:15333.</a></li><li><a class="nounderline abstract_t">Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357:605.</a></li><li><a class="nounderline abstract_t">Sivasothy P, Dafforn TR, Gettins PG, Lomas DA. Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. J Biol Chem 2000; 275:33663.</a></li><li><a class="nounderline abstract_t">Parfrey H, Dafforn TR, Belorgey D, et al. Inhibiting polymerization: new therapeutic strategies for Z alpha1-antitrypsin-related emphysema. Am J Respir Cell Mol Biol 2004; 31:133.</a></li><li><a class="nounderline abstract_t">Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology 2007; 45:1313.</a></li><li><a class="nounderline abstract_t">Propst T, Propst A, Dietze O, et al. High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin deficiency and chronic liver disease. Ann Intern Med 1992; 117:641.</a></li><li><a class="nounderline abstract_t">Mostafavi B, Piitulainen E, Tanash HA. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years. Int J Chron Obstruct Pulmon Dis 2019; 14:525.</a></li><li><a class="nounderline abstract_t">Teckman JH, Rosenthal P, Abel R, et al. Baseline Analysis of a Young α-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. J Pediatr Gastroenterol Nutr 2015; 61:94.</a></li><li><a class="nounderline abstract_t">Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand 1988; 77:847.</a></li><li><a class="nounderline abstract_t">Hussain M, Mieli-Vergani G, Mowat AP. Alpha 1-antitrypsin deficiency and liver disease: clinical presentation, diagnosis and treatment. J Inherit Metab Dis 1991; 14:497.</a></li><li><a class="nounderline abstract_t">Zhou H, Ortiz-Pallardó ME, Ko Y, Fischer HP. Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 2000; 88:2668.</a></li><li><a class="nounderline abstract_t">Fischer HP, Ortiz-Pallardó ME, Ko Y, et al. Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ. J Hepatol 2000; 33:883.</a></li><li><a class="nounderline abstract_t">Bals R. Alpha-1-antitrypsin deficiency. Best Pract Res Clin Gastroenterol 2010; 24:629.</a></li><li><a class="nounderline abstract_t">Clark VC, Marek G, Liu C, et al. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. J Hepatol 2018; 69:1357.</a></li><li><a class="nounderline abstract_t">Bowlus CL, Willner I, Zern MA, et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol 2005; 3:390.</a></li><li><a class="nounderline abstract_t">Clark VC, Dhanasekaran R, Brantly M, et al. Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency. Clin Gastroenterol Hepatol 2012; 10:1278.</a></li><li><a class="nounderline abstract_t">Strnad P, McElvaney NG, Lomas DA. Alpha1-Antitrypsin Deficiency. N Engl J Med 2020; 382:1443.</a></li><li><a class="nounderline abstract_t">Dawwas MF, Davies SE, Griffiths WJ, et al. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am J Respir Crit Care Med 2013; 187:502.</a></li><li><a class="nounderline abstract_t">Hamesch K, Mandorfer M, Pereira VM, et al. Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology 2019; 157:705.</a></li><li><a class="nounderline abstract_t">Schneider CV, Hamesch K, Gross A, et al. Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers. Gastroenterology 2020; 159:534.</a></li><li><a class="nounderline abstract_t">Pons M, Núñez A, Esquinas C, et al. Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol 2012; 10:575.</a></li><li><a class="nounderline abstract_t">Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008; 40:1492.</a></li><li><a class="nounderline abstract_t">Carey EJ, Iyer VN, Nelson DR, et al. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis. Liver Transpl 2013; 19:1370.</a></li><li><a class="nounderline abstract_t">Strnad P, Mandorfer M, Choudhury G, et al. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency. N Engl J Med 2022; 387:514.</a></li><li><a class="nounderline abstract_t">Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365:2225.</a></li><li><a class="nounderline abstract_t">Pittelkow MR, Smith KC, Su WP. Alpha-1-antitrypsin deficiency and panniculitis. Perspectives on disease relationship and replacement therapy. Am J Med 1988; 84:80.</a></li><li><a class="nounderline abstract_t">Edmonds BK, Hodge JA, Rietschel RL. Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature. Pediatr Dermatol 1991; 8:296.</a></li><li><a class="nounderline abstract_t">Stoller, JK, Piliang, M. Panniculitis in alpha-1 antitrypsin deficiency. Clin Pulm Med 2008; 15:113.</a></li><li><a class="nounderline abstract_t">Geraminejad P, DeBloom JR 2nd, Walling HW, et al. Alpha-1-antitrypsin associated panniculitis: the MS variant. J Am Acad Dermatol 2004; 51:645.</a></li><li><a class="nounderline abstract_t">Irvine C, Neild V, Stephens C, Black M. Alpha-1-antitrypsin deficiency panniculitis. J R Soc Med 1990; 83:743.</a></li><li><a class="nounderline abstract_t">Sorsa T, Lindy O, Konttinen YT, et al. Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase and gelatinase. Antimicrob Agents Chemother 1993; 37:592.</a></li><li><a class="nounderline abstract_t">O'Riordan K, Blei A, Rao MS, Abecassis M. alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation 1997; 63:480.</a></li><li><a class="nounderline abstract_t">Gross B, Grebe M, Wencker M, et al. New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology 2009; 218:370.</a></li><li><a class="nounderline abstract_t">Blanco I, Lipsker D, Lara B, Janciauskiene S. Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update. Br J Dermatol 2016; 174:753.</a></li><li><a class="nounderline abstract_t">Chng WJ, Henderson CA. Suppurative panniculitis associated with alpha 1-antitrypsin deficiency (PiSZ phenotype) treated with doxycycline. Br J Dermatol 2001; 144:1282.</a></li><li><a class="nounderline abstract_t">Schievink WI, Björnsson J, Parisi JE, Prakash UB. Arterial fibromuscular dysplasia associated with severe alpha 1-antitrypsin deficiency. Mayo Clin Proc 1994; 69:1040.</a></li><li><a class="nounderline abstract_t">Cox DW. Alpha 1-antitrypsin: a guardian of vascular tissue. Mayo Clin Proc 1994; 69:1123.</a></li><li><a class="nounderline abstract_t">Manderstedt E, Halldén C, Lind-Halldén C, et al. Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study. J Thromb Haemost 2022; 20:1421.</a></li><li><a class="nounderline abstract_t">Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 1983; 309:694.</a></li><li><a class="nounderline abstract_t">Yang P, Tremaine WJ, Meyer RL, Prakash UB. Alpha1-antitrypsin deficiency and inflammatory bowel diseases. Mayo Clin Proc 2000; 75:450.</a></li><li><a class="nounderline abstract_t">Elzouki AN, Eriksson S, Löfberg R, et al. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis 1999; 5:246.</a></li><li><a class="nounderline abstract_t">Folwaczny C, Urban S, Schröder M, et al. Alpha1-antitrypsin alleles and phenotypes in patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33:78.</a></li><li><a class="nounderline abstract_t">Davis ID, Burke B, Freese D, et al. The pathologic spectrum of the nephropathy associated with alpha 1-antitrypsin deficiency. Hum Pathol 1992; 23:57.</a></li><li><a class="nounderline abstract_t">Strife CF, Hug G, Chuck G, et al. Membranoproliferative glomerulonephritis and alpha 1-antitrypsin deficiency in children. Pediatrics 1983; 71:88.</a></li><li><a class="nounderline abstract_t">Moroz SP, Cutz E, Balfe JW, Sass-Kortsak A. Membranoproliferative glomerulonephritis in childhood cirrhosis associated with alpha1-antitrypsin deficiency. Pediatrics 1976; 57:232.</a></li><li><a class="nounderline abstract_t">Roy LP, Webster HL. alpha 1-Antitrypsin and membranoproliferative glomerulonephritis. Pediatrics 1977; 60:784.</a></li><li><a class="nounderline abstract_t">Noble-Jamieson G, Thiru S, Johnston P, et al. Glomerulonephritis with end-stage liver disease in childhood. Lancet 1992; 339:706.</a></li><li><a class="nounderline abstract_t">Ting SM, Toth T, Caskey F. alpha1-antitrypsin (A1AT) deficiency presenting with IgA nephropathy and nephrotic syndrome: is renal involvement caused by A1AT deposition? Clin Nephrol 2008; 70:159.</a></li><li><a class="nounderline abstract_t">Showkat A, Wall BM, Cooke CR. Cirrhosis and IgA nephropathy related to the PiSZ phenotype of alpha1-antitrypsin deficiency. Clin Nephrol 2005; 63:496.</a></li><li><a class="nounderline abstract_t">Esnault VL, Testa A, Audrain M, et al. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43:1329.</a></li><li><a class="nounderline abstract_t">O'Donoghue DJ, Guickian M, Blundell G, Winney RJ. Alpha-1-proteinase inhibitor and pulmonary haemorrhage in systemic vasculitis. Adv Exp Med Biol 1993; 336:331.</a></li><li><a class="nounderline abstract_t">Mahr AD, Edberg JC, Stone JH, et al. Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum 2010; 62:3760.</a></li><li><a class="nounderline abstract_t">Rahmattulla C, Mooyaart AL, van Hooven D, et al. Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann Rheum Dis 2016; 75:1687.</a></li><li><a class="nounderline abstract_t">Morris H, Morgan MD, Wood AM, et al. ANCA-associated vasculitis is linked to carriage of the Z allele of α₁ antitrypsin and its polymers. Ann Rheum Dis 2011; 70:1851.</a></li><li><a class="nounderline abstract_t">Esnault VL, Audrain MA, Sesboüé R. Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: one of several arguments for protease/antiprotease imbalance in systemic vasculitis. Exp Clin Immunogenet 1997; 14:206.</a></li><li><a class="nounderline abstract_t">Griffith ME, Lovegrove JU, Gaskin G, et al. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996; 11:438.</a></li><li><a class="nounderline abstract_t">Voorzaat BM, van Schaik J, Crobach SL, et al. Alpha-1 Antitrypsin Deficiency Presenting with MPO-ANCA Associated Vasculitis and Aortic Dissection. Case Rep Med 2017; 2017:8140641.</a></li><li><a class="nounderline abstract_t">Moxey JM, Low EV, Turner AM. Rare case of eosinophilic granulomatosis with polyangiitis in two patients with α-1-antitrypsin deficiency (PiSZ). BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Figueira Gonçalves JM, D'amato R. Antineutrophil cytoplasmic antibodies (ANCA)-negative vasculitis in a patient with alpha-1-antitrypsin deficiency. Arch Bronconeumol 2016; 52:172.</a></li></ol></div><div id="topicVersionRevision">Topic 1429 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://omim.org/entry/107400" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : http://omim.org/entry/107400 (Accessed on June 29, 2015).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27824593" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The prevalence of diagnosedα1-antitrypsin deficiency and its comorbidities: results from a large population-based database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1083485" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/309708" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485248" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4182334" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194472" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18796107" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Liver disease in alpha 1-antitrypsin deficiency: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35361631" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cancer risk in severe alpha-1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522813" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682522" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751191" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genetic variants of alpha1-antitrypsin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1905728" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486938" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1749216" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Alpha 1-antitrypsin deficiency and liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2254451" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15170041" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8938188" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090762" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8340361" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Alpha 1-antitrypsin Siiyama (Ser53--&gt;Phe). Further evidence for intracellular loop-sheet polymerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1608473" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The mechanism of Z alpha 1-antitrypsin accumulation in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10924508" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016619" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inhibiting polymerization: new therapeutic strategies for Z alpha1-antitrypsin-related emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464974" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1530195" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin deficiency and chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880942" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651489" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Baseline Analysis of a Youngα-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2905108" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The natural history of liver disease in alpha 1-antitrypsin deficient children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1749215" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Alpha 1-antitrypsin deficiency and liver disease: clinical presentation, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10870048" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11131449" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955965" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alpha-1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138687" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15822045" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22835581" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Liver test results do not identify liver disease in adults withα(1)-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32268028" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Alpha1-Antitrypsin Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23262512" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31121167" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32376409" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33923569" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22200689" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diagnosis and management of patients withα1-antitrypsin (A1AT) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18589136" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Alpha-1-antitrypsin deficiency: outcomes after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019185" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748699" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15978931" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3260076" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Alpha-1-antitrypsin deficiency and panniculitis. Perspectives on disease relationship and replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1792202" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Panniculitis in alpha-1 antitrypsin deficiency</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389208" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Alpha-1-antitrypsin associated panniculitis: the MS variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2250276" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Alpha-1-antitrypsin deficiency panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8384819" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase and gelatinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039946" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19218787" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26595240" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422069" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Suppurative panniculitis associated with alpha 1-antitrypsin deficiency (PiSZ phenotype) treated with doxycycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7967755" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Arterial fibromuscular dysplasia associated with severe alpha 1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7967770" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Alpha 1-antitrypsin: a guardian of vascular tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35263815" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6604220" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807072" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Alpha1-antitrypsin deficiency and inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10579117" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9489912" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Alpha1-antitrypsin alleles and phenotypes in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1544671" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The pathologic spectrum of the nephropathy associated with alpha 1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6600289" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Membranoproliferative glomerulonephritis and alpha 1-antitrypsin deficiency in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1082572" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Membranoproliferative glomerulonephritis in childhood cirrhosis associated with alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/303348" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : alpha 1-Antitrypsin and membranoproliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347585" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Glomerulonephritis with end-stage liver disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18793532" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : alpha1-antitrypsin (A1AT) deficiency presenting with IgA nephropathy and nephrotic syndrome: is renal involvement caused by A1AT deposition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15960154" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cirrhosis and IgA nephropathy related to the PiSZ phenotype of alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315946" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296629" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Alpha-1-proteinase inhibitor and pulmonary haemorrhage in systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20827781" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443607" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Genetic variants in ANCA-associated vasculitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21821620" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : ANCA-associated vasculitis is linked to carriage of the Z allele ofα₁antitrypsin and its polymers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9493789" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: one of several arguments for protease/antiprotease imbalance in systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671812" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28367219" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Alpha-1 Antitrypsin Deficiency Presenting with MPO-ANCA Associated Vasculitis and Aortic Dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118743" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rare case of eosinophilic granulomatosis with polyangiitis in two patients withα-1-antitrypsin deficiency (PiSZ).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603444" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antineutrophil cytoplasmic antibodies (ANCA)-negative vasculitis in a patient with alpha-1-antitrypsin deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
